Research Papers:

Mcl-1 inhibitor suppresses tumor growth of esophageal squamous cell carcinoma in a mouse model

Jianqing Lin, Deqiang Fu, Yijun Dai, Jianguang Lin and Tianwen Xu _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:114457-114462. https://doi.org/10.18632/oncotarget.18772

Metrics: PDF 1750 views  |   HTML 2321 views  |   ?  


Jianqing Lin1, Deqiang Fu1, Yijun Dai1, Jianguang Lin1 and Tianwen Xu1

1Department of Medical Oncology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, China

Correspondence to:

Tianwen Xu, email: [email protected]

Keywords: ESCC, Mcl-1, A-1210477

Received: January 10, 2017     Accepted: March 21, 2017     Published: June 28, 2017


Esophageal squamous cell carcinoma (ESCC) has a high morbidity in China, accounting for 90% of all esophageal carcinoma cases. Hence, identifying drug targets for prevention and treatment of ESCC is essential. Due to its critical role in the regulation of cell apoptosis, Mcl-1 holds great potential as a target for treatment against ESCC. In current study, we used a 4-nitroquinoline-1-oxide (4-NQO)-induced ESCC mouse model of test whether A-1210477, a Mcl-1 small molecular inhibitor, could repress ESCC development. We showed that A-1210477 treatment decreased ESCC formation and animal weight loss in a dose dependent manner. We detected decreased cellular proliferation in A-1210477-treated ESCC tissue by Ki67 expression. Moreover, A-1210477 treatment increased the number of apoptotic cells in ESCC tissues. Our study clearly demonstrates the contribution of Mcl-1 to ESCC development through promoting cell proliferation and inhibition of apoptosis, and provides a strong evidence for further evaluation of A-1210477 for treating ESCC.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 18772